Beginning on 10/19/18, Class C shares held for 10 years or more will automatically convert to Class A shares. Thereafter, Class C shares held for 10 years or more will automatically convert to Class A shares on a monthly basis. This conversion allows shareholders to take advantage of the lower expenses offered by Class A shares. Please see the prospectus supplement for more information. If you have any questions, please contact your financial advisor or call Franklin Templeton.
Effective 9/10/18, certain sales charges and commissions paid to dealers on Class A and A1 shares of our mutual funds changed. Please see the prospectus supplement for more information. If you have additional questions, please contact your financial advisor or call Franklin Templeton.
Total Fund AssetsAs of |
|
---|---|
Net Assets - Class |
|
P/E Ratio (12-mo Forward)As of |
|
---|---|
P/B RatioAs of |
|
[name] | [value] |
---|---|
Equity |
|
Cash & Cash Equivalents |
|
[name] | [value] |
---|---|
United States |
|
United Kingdom |
|
Cash & Cash Equivalents |
|
Denmark |
|
Canada |
|
Switzerland |
|
Netherlands |
|
[name] | [value] |
---|---|
Biotechnology |
|
Pharmaceuticals |
|
Life Sciences Tools & Services |
|
Cash & Cash Equivalents |
|
Diversified Capital Markets |
|
Other Diversified Financial Services |
|
[holdings-table-heading] | |
---|---|
GILEAD SCIENCES INC |
|
VERTEX PHARMACEUTICALS INC |
|
REGENERON PHARMACEUTICALS INC |
|
AMGEN INC |
|
ILLUMINA INC |
|
GW PHARMACEUTICALS PLC |
|
IOVANCE BIOTHERAPEUTICS INC |
|
NOVAVAX INC |
|
PTC THERAPEUTICS INC |
|
BIOGEN INC |
|
Performance data represents past performance, which does not guarantee future results. Current performance may differ from figures shown. Investment return and principal value will fluctuate with market conditions, and you may have a gain or loss when you sell your shares.